<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>BioNova Clinical Trials Graph</title>
  <meta name="description" content="Eighteen clinical trial MedicalTrial items with drug, medical organization, investigator, and framework links. Includes multi-phase progression path helper." />
</head>
<body>
  <header>
    <h1>BioNova Clinical Trials Graph</h1>
    <p>This file enumerates 18 clinical trial items spanning all major drugs, phases, and trial sites. Each trial links to its drug, medical organization, principal investigator, and compliance frameworks. Rich descriptions and explicit relationships support both vector and graph evaluation scenarios.</p>
  </header>

  <section>
    <h2>Clinical Trials</h2>
    <!-- Example trial: Oncora Phase III -->
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/oncora-phase-iii">
      <h3 itemprop="name">Oncora Phase III Efficacy Study</h3>
      <p itemprop="description">Randomized, double-blind, multicenter trial evaluating Oncora's efficacy and safety in advanced solid tumor patients. Primary endpoint: progression-free survival. Enrollment: 420. Start: 2024-01-15. End: 2025-09-30.</p>
      <meta itemprop="identifier" content="TRIAL-ONCORA-III" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/oncora" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/eastern-oncology-center" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/global-phaseiii-consortium" />
      <section>
        <h4>Principal Investigator</h4>
        <a itemprop="investigator" href="https://bionova.example/id/person/asclepius">Dr. Asclepius</a>
      </section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/fda-compliance" />
    </article>

    <!-- Oncora-XR Preclinical Release -->
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/oncora-xr-preclinical-release">
      <h3 itemprop="name">Oncora-XR Preclinical Release Study</h3>
      <p itemprop="description">Preclinical safety and pharmacokinetics study of Oncora-XR in murine and canine models. Focus: dose proportionality, tissue distribution, and early toxicity signals. Enrollment: 60. Start: 2023-03-01. End: 2023-09-15.</p>
      <meta itemprop="identifier" content="TRIAL-ONCORA-XR-PRECLIN" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/oncora-xr" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/oncology-trial-site-a" />
      <section>
        <h4>Principal Investigator</h4>
        <a itemprop="investigator" href="https://bionova.example/id/person/athena">Dr. Athena</a>
      </section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/fda-compliance" />
    </article>

    <!-- Cardiozen Phase III -->
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/cardiozen-phase-iii">
      <h3 itemprop="name">Cardiozen Phase III Cardiovascular Outcomes</h3>
      <p itemprop="description">Multinational, placebo-controlled trial assessing Cardiozen's impact on major adverse cardiovascular events in high-risk patients. Enrollment: 800. Start: 2024-05-10. End: 2026-02-28.</p>
      <meta itemprop="identifier" content="TRIAL-CARDIOZEN-III" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/cardiozen" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/northern-cardiology-institute" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/global-phaseiii-consortium" />
      <section>
        <h4>Principal Investigator</h4>
        <a itemprop="investigator" href="https://bionova.example/id/person/hippocrates">Dr. Hippocrates</a>
      </section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
    </article>

    <!-- Immunex Phase II -->
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/immunex-phase-ii">
      <h3 itemprop="name">Immunex Phase II Autoimmune Biomarker Study</h3>
      <p itemprop="description">Phase II trial evaluating Immunex's efficacy in autoimmune biomarker modulation. Primary endpoint: reduction in ANA titers. Enrollment: 150. Start: 2023-11-01. End: 2024-10-15.</p>
      <meta itemprop="identifier" content="TRIAL-IMMUNEX-II" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/immunex" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/western-immunology-clinic" />
      <section>
        <h4>Principal Investigator</h4>
        <a itemprop="investigator" href="https://bionova.example/id/person/panacea">Dr. Panacea</a>
      </section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
    </article>

    <!-- Immunex-Plus Preclinical Safety -->
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/immunex-plus-preclinical-safety">
      <h3 itemprop="name">Immunex-Plus Preclinical Safety Study</h3>
      <p itemprop="description">Toxicology and safety assessment of Immunex-Plus in rodent and primate models. Focus: immunogenicity, cytokine release, and off-target effects. Enrollment: 40. Start: 2023-06-01. End: 2023-12-01.</p>
      <meta itemprop="identifier" content="TRIAL-IMMUNEX-PLUS-PRECLIN" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/immunex-plus" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/immunology-trial-site-a" />
      <section>
        <h4>Principal Investigator</h4>
        <a itemprop="investigator" href="https://bionova.example/id/person/meditrina">Dr. Meditrina</a>
      </section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/fda-compliance" />
    </article>

    <!-- Neurova Phase I -->
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/neurova-phase-i">
      <h3 itemprop="name">Neurova Phase I Dose Escalation</h3>
      <p itemprop="description">First-in-human, open-label, dose-escalation study of Neurova in healthy volunteers. Primary endpoint: maximum tolerated dose. Enrollment: 32. Start: 2024-02-01. End: 2024-07-15.</p>
      <meta itemprop="identifier" content="TRIAL-NEUROVA-I" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/neurova" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/central-neuroscience-institute" />
      <section>
        <h4>Principal Investigator</h4>
        <a itemprop="investigator" href="https://bionova.example/id/person/chiron">Dr. Chiron</a>
      </section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
    </article>

    <!-- Vitalis Postmarketing Study -->
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/vitalis-postmarketing-study">
      <h3 itemprop="name">Vitalis Postmarketing Real-World Evidence Study</h3>
      <p itemprop="description">Observational study collecting real-world safety and effectiveness data for Vitalis in diverse patient populations. Enrollment: 1200. Start: 2025-01-01. End: 2027-06-30.</p>
      <meta itemprop="identifier" content="TRIAL-VITALIS-POSTMARKET" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/vitalis" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/postmarketing-registry-network" />
      <section>
        <h4>Principal Investigator</h4>
        <a itemprop="investigator" href="https://bionova.example/id/person/anchiale">Dr. Anchiale</a>
      </section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/fda-compliance" />
    </article>
    <!-- Expanded additional trials (11 total to reach 18) -->
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/oncora-dose-optimization">
      <h3 itemprop="name">Oncora Phase II Dose Optimization Study</h3>
      <p itemprop="description">Adaptive, open-label trial refining Oncora dosing through pharmacokinetic and pharmacodynamic modeling. Enrollment: 180. Start: 2023-06-01. End: 2024-04-30.</p>
      <meta itemprop="identifier" content="TRIAL-ONCORA-DOSE-OPT" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/oncora" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/eastern-oncology-center" />
      <section><h4>Principal Investigator</h4><a itemprop="investigator" href="https://bionova.example/id/person/chronos">Dr. Chronos</a></section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
    </article>
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/cardiozen-dose-ranging">
      <h3 itemprop="name">Cardiozen Phase II Dose Ranging Study</h3>
      <p itemprop="description">Randomized, controlled dose-ranging trial assessing Cardiozen hemodynamic responses across four titration arms. Enrollment: 260. Start: 2023-12-01. End: 2024-11-20.</p>
      <meta itemprop="identifier" content="TRIAL-CARDIOZEN-DOSE" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/cardiozen" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/northern-cardiology-institute" />
      <section><h4>Principal Investigator</h4><a itemprop="investigator" href="https://bionova.example/id/person/ares">Dr. Ares</a></section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
    </article>
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/immunex-biomarker-extension">
      <h3 itemprop="name">Immunex Biomarker Extension Study</h3>
      <p itemprop="description">Extension cohort analyzing sustained autoimmune biomarker modulation after initial Immunex Phase II endpoints. Enrollment: 90. Start: 2024-11-01. End: 2025-07-31.</p>
      <meta itemprop="identifier" content="TRIAL-IMMUNEX-EXT" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/immunex" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/western-immunology-clinic" />
      <section><h4>Principal Investigator</h4><a itemprop="investigator" href="https://bionova.example/id/person/hygieia">Dr. Hygieia</a></section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
    </article>
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/immunex-plus-dosing-strategy">
      <h3 itemprop="name">Immunex-Plus Dosing Strategy Optimization Study</h3>
      <p itemprop="description">Preclinical to early translational bridging study establishing combination dosing windows for Immunex-Plus components. Enrollment: 55. Start: 2024-02-01. End: 2024-09-30.</p>
      <meta itemprop="identifier" content="TRIAL-IMMUNEX-PLUS-DOSE" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/immunex-plus" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/immunology-trial-site-b" />
      <section><h4>Principal Investigator</h4><a itemprop="investigator" href="https://bionova.example/id/person/coeus">Dr. Coeus</a></section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/fda-compliance" />
    </article>
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/neurova-cognitive-biomarker">
      <h3 itemprop="name">Neurova Cognitive Biomarker Validation Study</h3>
      <p itemprop="description">Phase Ib exploratory cohort validating digital cognitive endpoints and CSF biomarkers for Neurova future efficacy trials. Enrollment: 48. Start: 2024-08-01. End: 2025-03-15.</p>
      <meta itemprop="identifier" content="TRIAL-NEUROVA-COG" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/neurova" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/central-neuroscience-institute" />
      <section><h4>Principal Investigator</h4><a itemprop="investigator" href="https://bionova.example/id/person/chiron">Dr. Chiron</a></section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
    </article>
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/vitalis-rare-disease-registry">
      <h3 itemprop="name">Vitalis Rare Disease Global Registry</h3>
      <p itemprop="description">Prospective observational registry tracking metabolic correction and safety in global rare disease populations receiving Vitalis. Enrollment: 1600. Start: 2025-03-01. End: 2028-12-31.</p>
      <meta itemprop="identifier" content="TRIAL-VITALIS-REGISTRY" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/vitalis" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/global-rare-disease-network" />
      <section><h4>Principal Investigator</h4><a itemprop="investigator" href="https://bionova.example/id/person/ananke">Dr. Ananke</a></section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/fda-compliance" />
    </article>
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/oncora-xr-steady-state">
      <h3 itemprop="name">Oncora-XR Steady-State Exposure Study</h3>
      <p itemprop="description">Single and multiple dose pharmacokinetic profiling for Oncora-XR to characterize steady-state plasma levels. Enrollment: 72. Start: 2024-05-15. End: 2025-01-30.</p>
      <meta itemprop="identifier" content="TRIAL-ONCORA-XR-STEADY" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/oncora-xr" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/oncology-trial-site-b" />
      <section><h4>Principal Investigator</h4><a itemprop="investigator" href="https://bionova.example/id/person/selene">Dr. Selene</a></section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
    </article>
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/immunex-pharmacodynamic-correlation">
      <h3 itemprop="name">Immunex Pharmacodynamic Correlation Study</h3>
      <p itemprop="description">Phase II substudy correlating Immunex plasma levels with specific cytokine suppression trajectories. Enrollment: 110. Start: 2024-01-10. End: 2024-12-20.</p>
      <meta itemprop="identifier" content="TRIAL-IMMUNEX-PD" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/immunex" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/immunology-trial-site-c" />
      <section><h4>Principal Investigator</h4><a itemprop="investigator" href="https://bionova.example/id/person/dike">Dr. Dike</a></section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
    </article>
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/cardiozen-quality-of-life">
      <h3 itemprop="name">Cardiozen Quality of Life Outcomes Study</h3>
      <p itemprop="description">Prospective assessment of patient-reported functional status improvements under Cardiozen therapy. Enrollment: 300. Start: 2024-03-01. End: 2025-06-30.</p>
      <meta itemprop="identifier" content="TRIAL-CARDIOZEN-QOL" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/cardiozen" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/northern-cardiology-institute" />
      <section><h4>Principal Investigator</h4><a itemprop="investigator" href="https://bionova.example/id/person/salus">Dr. Salus</a></section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
    </article>
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/neurova-drug-drug-interaction">
      <h3 itemprop="name">Neurova Drug-Drug Interaction Phase I Substudy</h3>
      <p itemprop="description">Evaluates Neurova interaction potential with standard-of-care agents via cytochrome modulation and cognitive performance comparisons. Enrollment: 36. Start: 2024-06-01. End: 2024-12-15.</p>
      <meta itemprop="identifier" content="TRIAL-NEUROVA-DDI" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/neurova" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/central-neuroscience-institute" />
      <section><h4>Principal Investigator</h4><a itemprop="investigator" href="https://bionova.example/id/person/nyx">Dr. Nyx</a></section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/ich-gcp-compliance" />
    </article>
    <article itemscope itemtype="https://schema.org/MedicalTrial" itemid="https://bionova.example/id/trial/vitalis-long-term-safety">
      <h3 itemprop="name">Vitalis Long-Term Safety Follow-Up Study</h3>
      <p itemprop="description">Extended observation study tracking chronic safety events and metabolic stability over multiple years of Vitalis therapy. Enrollment: 900. Start: 2025-05-01. End: 2030-04-30.</p>
      <meta itemprop="identifier" content="TRIAL-VITALIS-LT" />
      <link itemprop="studySubject" href="https://bionova.example/id/drug/vitalis" />
      <link itemprop="location" href="https://bionova.example/id/medical-org/global-rare-disease-network" />
      <section><h4>Principal Investigator</h4><a itemprop="investigator" href="https://bionova.example/id/person/panacea">Dr. Panacea</a></section>
      <link itemprop="citation" href="https://bionova.example/id/policy/framework/fda-compliance" />
    </article>
  </section>

  <!-- Path Helper: Oncora Family Trial Progression -->
  <section itemscope itemtype="https://schema.org/CreativeWork" itemid="https://bionova.example/id/path/oncora-family-trial-progression" data-rel="path" data-hops="3">
    <meta itemprop="name" content="Oncora Family Trial Progression" />
    <p itemprop="description">Oncora-XR Preclinical Release → Oncora Dose Optimization → Oncora Phase III</p>
    <link itemprop="about" href="https://bionova.example/id/trial/oncora-xr-preclinical-release" />
    <link itemprop="about" href="https://bionova.example/id/trial/oncora-dose-optimization" />
    <link itemprop="about" href="https://bionova.example/id/trial/oncora-phase-iii" />
  </section>
</body>
</html>
